Thomas J. Ferro

2.1k total citations
54 papers, 1.7k citations indexed

About

Thomas J. Ferro is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology. According to data from OpenAlex, Thomas J. Ferro has authored 54 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 24 papers in Physiology and 14 papers in Immunology. Recurrent topics in Thomas J. Ferro's work include Asthma and respiratory diseases (15 papers), Nitric Oxide and Endothelin Effects (9 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (8 papers). Thomas J. Ferro is often cited by papers focused on Asthma and respiratory diseases (15 papers), Nitric Oxide and Endothelin Effects (9 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (8 papers). Thomas J. Ferro collaborates with scholars based in United States, Germany and Canada. Thomas J. Ferro's co-authors include Shijian Chu, A. Johnson, Asrar B. Malik, Denise C. Hocking, Joseph J. Lynch, F. A. Blumenstock, Patricia G. Phillips, Christopher Horvath, Gary Jesmok and Nancy Gertzberg and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and The Journal of Immunology.

In The Last Decade

Thomas J. Ferro

54 papers receiving 1.6k citations

Peers

Countries citing papers authored by Thomas J. Ferro

Since Specialization

Citations

This map shows the geographic impact of Thomas J. Ferro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas J. Ferro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas J. Ferro more than expected).

Fields of papers citing papers by Thomas J. Ferro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas J. Ferro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas J. Ferro. The network helps show where Thomas J. Ferro may publish in the future.

Co-authorship network of co-authors of Thomas J. Ferro

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas J. Ferro. A scholar is included among the top collaborators of Thomas J. Ferro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas J. Ferro. Thomas J. Ferro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis 2025 ·Dermatology and Therapy ·Mark Lebwohl, André Lopes Carvalho, Akihiko Asahina, Jianzhong Zhang, Mir Sohail Fazeli, (unknown), Paul Serafini, Thomas J. Ferro, (unknown), Diamant Thaçi	1
2	Improvement in Patient-reported Symptoms and Satisfaction with Tildrakizumab in a Real-world Study in Patients with Moderate-to-severe Plaque Psoriasis 2024 ·PubMed Central ·(unknown), (unknown), Tina Bhutani, John Koo, Jacob Mathew, Thomas J. Ferro, Neal Bhatia	1
3	Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis 2024 ·Journal of Drugs in Dermatology ·(unknown), (unknown), Tina Bhutani, John Koo, Jacob Mathew, (unknown), Thomas J. Ferro, Neal Bhatia	4
4	Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis 2024 ·Dermatology and Therapy ·Tina Bhutani, John Koo, (unknown), Neal Bhatia, Jacob Mathew, Thomas J. Ferro, (unknown)	1
5	Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils 2023 ·Journal of Immunology Research ·Eugene R. Bleecker, Reynold A. Panettieri, Njira Lugogo, Jonathan Corren, Nadia Daizadeh, Juby A. Jacob‐Nara, Yamo Deniz, Paul J. Rowe, (unknown), Xavier Soler, Thomas J. Ferro, (unknown)	2
6	Racial and Ethnic Minorities at the Highest Risk of Uncontrolled Moderate-to-Severe Asthma: A United States Electronic Health Record Analysis 2023 ·Journal of Asthma and Allergy ·Maureen George, Carlos A. Camargo, (unknown), (unknown), Ajinkya Pawar, (unknown), (unknown), Michael A. Wells, Thomas J. Ferro	3
7	Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events 2020 ·Journal of Cystic Fibrosis ·C. Schwarz, Sivagurunathan Sutharsan, Ralph Epaud, Ross C. Klingsberg, Rainald Fischer, Steven M. Rowe, Paul Audhya, Neil Ahluwalia, Xiaojun You, Thomas J. Ferro, Margaret E. Duncan, Bote G. Bruinsma	18
8	Comparing Ran-Out Status of Inhaled Short-Acting Beta-Agonists in Emergency Department Patients with Acute Asthma: 1996-1998 versus 2015-2017 2018 ·The Journal of Allergy and Clinical Immunology In Practice ·Tadahiro Goto, Carlos A. Camargo, (unknown), Daniel J. Pallin, Nathan I. Shapiro, Thomas J. Ferro, (unknown), (unknown), Kohei Hasegawa	2
9	Real-world healthcare utilization in asthma patients using albuterol sulfate inhalation aerosol (ProAir® HFA) with and without integrated dose counters 2017 ·Journal of Asthma and Allergy ·Edward Kerwin, Thomas J. Ferro, Rinat Ariely, Debra E. Irwin, (unknown)	1
10	Body Mass Index and Response to Asthma Therapy: Fluticasone Propionate/Salmeterol versus Montelukast 2010 ·Journal of Asthma ·Carlos A. Camargo, Louis‐Philippe Boulet, E. Rand Sutherland, William W. Busse, Steven W. Yancey, Amanda Emmett, Héctor Ortega, Thomas J. Ferro	75
11	Poly(ADP-ribose) polymerase-1 regulates vimentin expression in lung cancer cells 2007 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Shijian Chu, (unknown), Thomas J. Ferro, (unknown)	22
12	Identification of a hydrogen peroxide-induced PP1-JNK1-Sp1 signaling pathway for gene regulation 2006 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Shijian Chu, Thomas J. Ferro	35
13	Sp1: Regulation of gene expression by phosphorylation 2005 ·Gene ·Shijian Chu, Thomas J. Ferro	210
14	Disappearance of Microalbuminuria in a Patient With Type 2 Diabetes and the Metabolic Syndrome in the Setting of an Intense Exercise and Dietary Program With Sustained Weight Reduction 2004 ·Diabetes Care ·Sonja K. Fredrickson, Thomas J. Ferro, (unknown)	19
15	Interferon-γ regulates ClC-2 chloride channel in lung epithelial cells 2004 ·Biochemical and Biophysical Research Communications ·Shijian Chu, Carol J. Blaisdell, Penelope Bamford, Thomas J. Ferro	13
16	Improving Adherence With Antimicrobial Therapy for Respiratory Tract Infections: A Discussion of Directly Observed Therapy (DOT) and Short-Course Therapies 2004 ·American Journal of Therapeutics ·Douglas B. Schwartz, A Adler, (unknown), Ronald J. DeBellis, (unknown), Thomas J. Ferro, (unknown), (unknown), Peggy S. McKinnon, Gregory Volturo	5
17	Expression of α-ENaC2 is dependent on an upstream Sp1 binding motif and is modulated by protein phosphatase 1 in lung epithelial cells 2003 ·Biochemical and Biophysical Research Communications ·Shijian Chu, (unknown), Thomas J. Ferro	23
18	Increased endothelial albumin permeability mediated by protein kinase C activation. 1990 ·Journal of Clinical Investigation ·Joseph J. Lynch, Thomas J. Ferro, F. A. Blumenstock, (unknown), Asrar B. Malik	221
19	Macrophages Activated by Fibrin Increase Albumin Permeability across Pulmonary Artery Endothelial Monolayers 1989 ·American Review of Respiratory Disease ·Thomas J. Ferro, Joseph J. Lynch, Asrar B. Malik	9
20	Carbohydrate Differences in HLA-DR Molecules Synthesized by Alveolar Macrophages and Blood Monocytes ^1– ³ 1987 ·American Review of Respiratory Disease ·Thomas J. Ferro, Dimitri Monos, Brett T. Spear, Milton D. Rossman, Chester M. Zmijewski, Malek Kamoun, Ronald P. Daniele	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact